Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Consistent stability data for Adventrx's ANX-530 to support NDA submission

Sep. 17, 2010

GTx-758 induces medical castration in phase II trial

Sep. 16, 2010

BioCryst presents data from forodesine oncology studies

Sep. 16, 2010

Synta Pharma expands phase II STA-9090 trial in NSCLC

Sep. 16, 2010

Cell Therapeutics to appeal FDA decision on NDA for pixantrone in NHL

Sep. 15, 2010

Diamyd to outlicense NP-2 following phase II trial in cancer

Sep. 15, 2010

Bristol-Myers Squibb generates backup IGF-I receptor inhibitor to BMS-754807 for cancer

Sep. 15, 2010

GNE-A shows preclinical potential as anticancer agent

Sep. 15, 2010

Ariad begins phase II trial of ponatinib in chronic myeloid leukemia

Sep. 14, 2010

Cyclacel and FDA agree on a special protocol assessment for phase III sapacitabine trial

Sep. 14, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...